

# **Drug Delivery in Central Nervous System Disorders**

## **Technologies, Companies and Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**December 2017**

**A Jain PharmaBiotech Report**

## **AUTHOR'S BIOGRAPHY**

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist's qualifications. His personal experience includes some of the technologies mentioned in this report. He received graduate training in both Europe and USA, and has held academic positions in several countries. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK and has been working in the biotechnology/biopharmaceuticals industry for several years. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, neurology, and pharmaceuticals.

Prof. Jain has edited "Drug Delivery to the Central Nervous System (Springer/Humana 2010)", and "Drug Delivery Systems", 2<sup>nd</sup> ed (Springer/Humana 2014)". Most recently he has edited "Applied Neurogenomics" (Springer 2015). Books authored by him include "Handbook of Nanomedicine (Springer 2008, Chinese edition, Peking University Press 2011, 3<sup>rd</sup> ed Springer 2017)", "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015)", "Handbook of Biomarkers (Springer 2010; Chinese edition, Chemical Industry Press, 2016, 2<sup>nd</sup> ed Springer 2017)", "Handbook of Neuroprotection (Springer 2011)", "Drug-induced Neurological Disorders, 3<sup>rd</sup> ed (Hogrefe 2011)", "Applications of Biotechnology in Neurology (Springer 2013)", and "Applications of Biotechnology in Oncology (Springer 2014)".

## **ABOUT THIS REPORT**

The original report on Drug Delivery in CNS Diseases by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was rewritten and published at Jain PharmaBiotech in 2004 and is being constantly rewritten since then.

**December 2017 (constantly updated since first edition published in 2000 by Decision Resources Inc) Copyright © 2017 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax: +4161-6924461  
Email: info@pharmabiotech.ch  
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>16</b>
<b>1. Basics of Drug Delivery to the Central Nervous System .....</b>	<b>18</b>
<b>Introduction .....</b>	<b>18</b>
<b>Historical evolution of drug delivery for CNS disorders.....</b>	<b>18</b>
<b>Neuroanatomical and neurophysiological basis of drug delivery.....</b>	<b>19</b>
The cerebrospinal fluid .....	19
The lymphatic drainage system of the brain .....	20
The extracellular space in the brain .....	20
Neurotransmitters.....	21
Extracellular vesicles as drug delivery vehicles .....	23
<b>Neuropharmacology relevant to drug delivery.....</b>	<b>23</b>
Introduction to neuropharmacology.....	23
Pharmacokinetics.....	23
<i>Absorption and distribution of drugs .....</i>	<i>23</i>
<i>Drug metabolism and elimination.....</i>	<i>24</i>
Pharmacodynamics .....	24
<i>Receptors .....</i>	<i>24</i>
Sites of drug action in the CNS .....	24
<i>Receptors coupled to guanine nucleotide binding proteins .....</i>	<i>25</i>
<i>Acetylcholine receptor channels .....</i>	<i>25</i>
<i>Dopamine receptors.....</i>	<i>25</i>
<i>GABA receptor channels.....</i>	<i>26</i>
<i>Glutamate receptor channels.....</i>	<i>26</i>
<i>Non-competitive NMDA antagonists.....</i>	<i>26</i>
<i>Serotonin receptors.....</i>	<i>27</i>
<i>G-protein coupled receptors .....</i>	<i>27</i>
In vivo study of drug action in the CNS in human patients .....	27
<i>Electroencephalography.....</i>	<i>27</i>
<i>Brain imaging.....</i>	<i>28</i>
Chronopharmacology as applied to the CNS .....	28
Role of drug delivery in personalized therapy of CNS disorders .....	29
<b>2. Blood Brain Barrier .....</b>	<b>30</b>
<b>Introduction .....</b>	<b>30</b>
<b>Features of the blood-brain barrier relevant to CNS drug delivery.....</b>	<b>30</b>
The neurovascular unit .....	30
Functions of the BBB .....	31
<i>BBB as an anatomical as well as physiological barrier .....</i>	<i>31</i>
<i>BBB as a biochemical barrier .....</i>	<i>32</i>
Role of shear stress on development of BBB.....	32
Genomics of BBB .....	33
Proteomics of BBB.....	33
<b>Other neural barriers .....</b>	<b>34</b>
Blood-cerebrospinal fluid barrier .....	34
Blood nerve barrier .....	34
Blood-retinal barrier .....	35
Blood-labyrinth barrier .....	35
<b>Passage of substances across the blood-brain barrier .....</b>	<b>35</b>
Transporters localized in the BBB.....	36
<i>Adenosine carrier.....</i>	<i>37</i>
<i>Amino acid transporters.....</i>	<i>37</i>
<i>Efflux transport systems .....</i>	<i>37</i>
<i>Glucose transporter.....</i>	<i>38</i>
<i>Ionic transporter.....</i>	<i>39</i>
BBB-specific enzymes.....	39
Receptor-mediated transcytosis .....	39
Lysophosphatidic acid-mediated increase in BBB permeability .....	40
Folate transport system .....	40
Transferrin receptor .....	40
Molecular biology of the BBB .....	41
Transport of peptides and proteins across the BBB.....	41
<i>Passage of leptin across the BBB.....</i>	<i>41</i>
<i>Passage of cytokines across the BBB .....</i>	<i>42</i>
<i>Passage of hormones across the BBB .....</i>	<i>42</i>
<i>Passage of enzymes across the BBB.....</i>	<i>43</i>
Passage of omega-3 fatty acids across the BBB .....	43

<i>Drugs that cross the BBB by binding to plasma proteins</i> .....	43
Current concepts of the permeability of the BBB .....	43
<b>Factors that increase the permeability of the BBB .....</b>	<b>44</b>
BBB disruption as an adverse effect of pharmaceuticals .....	45
BBB disruption as adverse effect of vaccines for CNS disorders .....	45
<b>CNS disorders and BBB .....</b>	<b>45</b>
Autoimmune disorders.....	46
Brain tumors .....	46
<i>Primary brain tumors</i> .....	46
<i>Cerebral metastases</i> .....	47
Central nervous system injuries.....	47
Cerebrovascular disease .....	48
<i>Cerebral ischemia</i> .....	48
<i>Intracerebral hemorrhage</i> .....	48
Epilepsy.....	48
Infections .....	49
Mitochondrial encephalopathies .....	49
Multiple sclerosis.....	50
Neurodegenerative disorders.....	51
<i>BBB in Alzheimer disease</i> .....	51
<i>BBB in Parkinson disease</i> .....	52
<i>BBB in amyotrophic lateral sclerosis</i> .....	52
West Nile virus infection .....	52
<b>Testing permeability of the BBB.....</b>	<b>53</b>
In vitro models of BBB.....	53
In vivo study of BBB.....	54
<i>Brain imaging</i> .....	54
In silico prediction of BBB .....	55
Relevance of the BBB penetration to pharmacological action .....	56
<i>BBB penetration and CNS drug screening</i> .....	56
<i>BBB models for testing drug delivery</i> .....	57
<i>CERENSE<sup>SM</sup></i> .....	57
<i>In vivo brain distribution of P-glycoprotein</i> .....	57
Transthyretin monomer as a marker of blood-CSF barrier disruption .....	58
Evaluation of BBB permeability by brain imaging .....	58
Biomarkers of disruption of blood-brain barrier .....	58
<b>Future directions for research on the BBB .....</b>	<b>58</b>
Use of neural stem cells to construct the blood brain barrier.....	59
<b>Strategies to cross the BBB.....</b>	<b>60</b>

### **3. Methods of Drug Delivery to the CNS .....**

<b>Introduction .....</b>	<b>62</b>
<b>Routes of drug delivery to the brain .....</b>	<b>63</b>
Drug deliveries to the brain via the nasal route .....	63
<i>Devices for nasal administration of drugs for CNS</i> .....	64
<i>Nasal mucosal patch to facilitate drug delivery across the BBB</i> .....	65
<i>Passage of viruses to the brain via the nasal route</i> .....	65
<i>Potential and limitations of nasal drug delivery to the brain</i> .....	65
Drugs that can be delivered to the brain via the nasal route.....	66
<i>Erythropoietin</i> .....	66
<i>Esketamine</i> .....	66
<i>Hypocretin</i> .....	66
<i>IFN beta-1b</i> .....	66
<i>Lysosomal enzymes</i> .....	67
<i>Midazolam</i> .....	67
<i>Neurotrophic factors</i> .....	67
<i>Thyrotropin-releasing hormone</i> .....	68
<i>Neuroprotective drugs for stroke</i> .....	68
Transdermal drug delivery for neurological disorders.....	69
Drug delivery to the brain via inner ear .....	69
Drug delivery for disorders of the spinal cord.....	69
Intrathecal drug delivery.....	69
<i>Anatomical &amp; physiological aspects of intrathecal drug delivery</i> .....	70
<i>Advantages of intrathecal drug delivery</i> .....	70
<i>Drugs that can be delivered by intrathecal route</i> .....	71
<i>Pharmacokinetics of intrathecal drug delivery</i> .....	72
<i>Retrograde delivery to the brain via the epidural venous system</i> .....	74
Devices for drug delivery to the CNS .....	74
<i>Catheters for drug delivery to the CNS</i> .....	74
<i>Reservoirs and pumps for drug delivery to the CNS</i> .....	75
Invasive neurosurgical approaches.....	75

<i>Intraarterial drug delivery to the brain</i> .....	75
<i>Direct injection into the CNS substance or CNS lesions</i> .....	76
<i>Targeted delivery of biologicals to the spinal cord by microinjection</i> .....	76
<i>Intraventricular injection of drugs</i> .....	77
<b>Strategies for drug delivery to the CNS across the BBB</b> .....	<b>77</b>
Increasing the permeability (opening) of the BBB .....	78
<i>Osmotic opening of the BBB</i> .....	78
<i>Focal disruption of BBB by ultrasound</i> .....	78
<i>Chemical opening of the BBB</i> .....	78
<i>Cerebral vasodilatation to open the BBB</i> .....	79
<i>Modulation of vascular permeability by laser irradiation</i> .....	79
<i>Neurostimulation for opening BBB</i> .....	80
<i>Use of nitric oxide donors to open the BBB</i> .....	80
<i>Manipulation of the sphingosine 1-phosphate receptor system</i> .....	80
Pharmacological strategies to facilitate transport across the BBB .....	81
<i>2B-Trans™ technology</i> .....	81
<i>ABC influx transporters and penetration of the BBB</i> .....	82
<i>Adenosine agonist-mediated drug delivery across the BBB</i> .....	83
<i>Carrier-mediated drug delivery across the BBB</i> .....	83
<i>Fusion of receptor-binding peptide from apoE with therapeutic protein</i> .....	84
<i>G-Technology®</i> .....	84
<i>Glycosylation Independent Lysosomal Targeting</i> .....	84
<i>Inhibition of P-glycoprotein to enhance drug delivery across the BBB</i> .....	85
<i>LipoBridge™ technology</i> .....	85
<i>Modification of the drug to enhance its lipid solubility</i> .....	85
<i>Monoclonal antibody fusion proteins</i> .....	86
<i>Neuroimmunophilins</i> .....	87
<i>Peptide-mediated transport across the BBB</i> .....	87
<i>Prodrug bioconversion strategies and their CNS selectivity</i> .....	89
<i>Transport of small molecules across the BBB</i> .....	89
<i>Transport across the BBB by short chain oligoglycerolipids</i> .....	89
<i>Transvascular delivery across the BBB</i> .....	90
<i>Trojan horse approach</i> .....	90
<i>Role of the transferrin-receptor system in CNS drug delivery</i> .....	91
<i>Use of receptor-mediated transcytosis to cross the BBB</i> .....	91
Cell-based drug delivery to the CNS .....	93
<i>Activated T lymphocytes</i> .....	93
<i>Microglial cells</i> .....	93
<i>Neural stem cells</i> .....	93
Drug delivery to the CNS by using novel formulations.....	94
<i>Crystalline formulations</i> .....	94
<i>Liposomes</i> .....	94
<i>Monoclonal antibodies</i> .....	95
<i>Microspheres</i> .....	96
<i>Microbeads</i> .....	96
Brain-targeted chemical delivery systems .....	97
<b>Nanotechnology-based drug delivery to CNS</b> .....	<b>98</b>
Nanoparticles for drug delivery across the BBB .....	98
<i>NanoDel™ technology for crossing the BBB</i> .....	98
<i>Masking BBB-limiting characteristics by nanotechnology</i> .....	99
<i>Nanovesicles for transport across BBB</i> .....	99
<i>Peptide-nanoparticle conjugates for crossing the BBB</i> .....	99
<i>Penetration of BBB by nanoparticles coated with polysorbate 80</i> .....	99
<i>Transcytosis of transferrin-containing nanoparticles across the BBB</i> .....	100
Nanotechnology-based devices and implants for CNS .....	100
<b>Biochip implants for drug delivery to the CNS</b> .....	<b>101</b>
Controlled-release microchip .....	101
Retinal implant chip .....	101
<b>Convection-enhanced delivery to the CNS</b> .....	<b>101</b>
<b>Systemic administration of drugs for CNS effects</b> .....	<b>102</b>
Sustained and controlled release drug delivery to the CNS .....	102
<i>Fast dissolving oral selegiline</i> .....	104
Choice of the route of systemic delivery for effect on the CNS disorders .....	104
<b>Methods of delivery of biopharmaceuticals to the CNS</b> .....	<b>105</b>
Delivery of biopharmaceuticals across the BBB .....	105
Methods of delivery of peptides for CNS disorders.....	105
<i>Alteration of properties of the BBB for delivery of peptides</i> .....	106
<i>Challenges for delivery of peptides across the BBB</i> .....	106
<i>CNS delivery of peptides via conjugation to biological carriers</i> .....	106
<i>Delivery of conopeptides to the brain</i> .....	106
<i>Direct delivery of neuropeptides into the brain</i> .....	107

<i>Molecular manipulations of peptides to facilitate transport into CNS</i> .....	107
<i>Transport to spinal cord motor neurons after peripheral injection</i> .....	108
<i>Transnasal administration of neuropeptides</i> .....	108
Delivery of neurotrophic factors to the nervous system .....	108
<i>Systemic administration of NTFs</i> .....	110
<i>Delivery systems to facilitate crossing of the BBB by NTFs</i> .....	111
<i>Direct application of NTFs to the CNS</i> .....	111
<i>Intracerebroventricular injection</i> .....	112
<i>Intrathecal administration</i> .....	113
<i>Implants for delivery of neurotrophic factors</i> .....	113
<i>Use of neurotrophic factor mimics</i> .....	113
<i>Use of microspheres for delivery of neurotrophic factors</i> .....	115
<i>Use of nanobiotechnology for delivery of neurotrophic factors</i> .....	115
<b>Use of microorganisms for therapeutic entry into the brain</b> .....	<b>116</b>
Bacteriophages as CNS therapeutics .....	116
<b>Intracellular drug delivery in the brain</b> .....	<b>116</b>
<b>Local factors in the brain affecting drug action</b> .....	<b>117</b>
<b>Methods for testing drug delivery to the CNS</b> .....	<b>117</b>
Animal models for testing drug delivery .....	117
Screening for drug-P-gp interaction at BBB .....	117
<b>4. Delivery of Cell, Gene and Antisense Therapies to the CNS</b> .....	<b>120</b>
<b>Introduction</b> .....	<b>120</b>
<b>Cell therapy of neurological disorders</b> .....	<b>120</b>
Methods for delivering cell therapies in CNS disorders .....	120
<i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i> .....	121
<i>Engineered stem cells for drug delivery to the brain</i> .....	121
<i>Encapsulated cells</i> .....	122
<i>Intrathecal delivery of stem cells</i> .....	122
<i>Intraparenchymal delivery of stem cells to the spinal cord</i> .....	123
<i>Intravascular administration</i> .....	123
<i>Neural stem cells as therapeutic delivery vehicles</i> .....	124
<b>Gene therapy techniques for the nervous system</b> .....	<b>124</b>
Introduction .....	124
Methods of gene transfer to the nervous system .....	126
AAV vector mediated gene therapy for neurogenetic disorders .....	126
Ideal vector for gene therapy of neurological disorders .....	126
Promoters of gene transfer .....	127
Routes of delivery of genes to the nervous system .....	127
<i>Direct injection into CNS</i> .....	127
<i>Introduction of the genes into cerebral circulation</i> .....	128
<i>Introduction of genes into cerebrospinal fluid</i> .....	128
<i>Intravenous administration of vectors</i> .....	129
<i>Delivery of gene therapy to the peripheral nervous system</i> .....	129
Cell-mediated gene therapy of neurological disorders .....	129
<i>Neuronal cells</i> .....	129
<i>Neural stem cells and progenitor cells</i> .....	129
<i>Astrocytes</i> .....	130
<i>Cerebral endothelial cells</i> .....	130
<i>Implantation of genetically modified encapsulated cells into the brain</i> .....	130
<i>Genetically modified bone marrow cells</i> .....	130
Nanoparticles as nonviral vectors for CNS gene therapy .....	131
Applications of gene therapy for neurological disorders .....	131
Companies involved in cell/gene therapy of neurological disorders .....	132
<b>Antisense therapy of CNS disorders</b> .....	<b>133</b>
Delivery of antisense oligonucleotides to the CNS .....	134
Delivery of oligonucleotides cross the BBB .....	135
Cellular delivery systems for oligonucleotides .....	136
High-flow microinfusion into the brain parenchyma .....	136
Systemic administration of peptide nucleic acids .....	136
Introduction of antisense compounds into the CSF Pathways .....	137
Intrathecal administration of antisense compounds .....	137
Intracerebroventricular administration of antisense oligonucleotides .....	137
Nanoparticle-based delivery of antisense therapy to the CNS .....	138
Methods of delivery of ribozymes .....	138
<b>Delivery aspects of RNAi therapy of CNS disorders</b> .....	<b>139</b>
Delivery of siRNA to the CNS .....	139
<b>Future drug delivery strategies applicable to the CNS</b> .....	<b>140</b>
<b>5. Drug Delivery for Treatment of Neurological Disorders</b> .....	<b>142</b>
<b>Introduction</b> .....	<b>142</b>

Targeted drug delivery for neurological disorders .....	142
<b>Parkinson's disease .....</b>	<b>142</b>
Drug delivery systems for Parkinson's disease .....	144
<i>Methods of delivery of levodopa in PD .....</i>	<i>145</i>
<i>Duodenal levodopa infusion.....</i>	<i>145</i>
<i>Sublingual apomorphine .....</i>	<i>146</i>
<i>Transdermal drug delivery for PD.....</i>	<i>146</i>
<i>Transdermal dopamine agonists for PD .....</i>	<i>146</i>
<i>Transdermal administration of other drugs for PD .....</i>	<i>148</i>
<i>Intracerebral administration of GDNF .....</i>	<i>148</i>
Cell therapy for PD .....	148
<i>Human dopaminergic neurons for PD.....</i>	<i>149</i>
<i>Graft survival-enhancing drugs.....</i>	<i>150</i>
<i>Xenografting porcine fetal neurons.....</i>	<i>150</i>
<i>Encapsulated cells for PD .....</i>	<i>151</i>
<i>Stem cells for PD .....</i>	<i>151</i>
<i>Engineered stem cells for drug delivery to the brain in PD .....</i>	<i>152</i>
<i>Human retinal pigment epithelium cells for PD.....</i>	<i>153</i>
<i>Delivery of cells for PD.....</i>	<i>153</i>
Gene therapy for Parkinson disease.....	154
<i>Rationale .....</i>	<i>154</i>
<i>Techniques of gene therapy for PD.....</i>	<i>155</i>
<i>Prospects of gene therapy for PD .....</i>	<i>158</i>
<i>Companies developing gene therapy for PD.....</i>	<i>159</i>
RNAi therapy of Parkinson's disease .....	159
<b>Alzheimer disease.....</b>	<b>160</b>
Drug delivery for Alzheimer disease .....	160
Blood-brain partitioning of an AMPA receptor modulator .....	161
Clearing amyloid through the BBB.....	162
Delivery of the passive antibody directly to the brain.....	162
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	162
Nanoparticle-based drug delivery for Alzheimer's disease.....	162
Perispinal etanercept.....	163
Slow release implant of an AChE inhibitor .....	164
Intranasal insulin in Alzheimer disease .....	164
Transdermal drug delivery in Alzheimer's disease.....	164
Trojan-horse approach to prevent build-up of A $\beta$ aggregates.....	165
Cell and gene therapy for Alzheimer disease.....	165
<i>NGF gene therapy.....</i>	<i>165</i>
<i>Neprilysin gene therapy.....</i>	<i>166</i>
RNAi therapy of Alzheimer's disease.....	167
<b>Huntington's disease .....</b>	<b>167</b>
Treatment of HD .....	167
Gene therapy of HD .....	168
<i>Encapsulated genetically engineered cellular implants.....</i>	<i>168</i>
<i>Viral vector mediated administration of neurotrophic factors .....</i>	<i>168</i>
<i>RNAi therapeutics for the treatment of HD .....</i>	<i>168</i>
<b>Amyotrophic lateral sclerosis.....</b>	<b>169</b>
Treatment of ALS.....	169
Drug delivery in ALS.....	169
Delivery of stem cell therapy for ALS.....	170
Gene and antisense therapy of ALS .....	171
<i>Neurotrophic factor gene therapies of ALS.....</i>	<i>171</i>
<i>Antisense therapy of ALS .....</i>	<i>173</i>
<i>RNAi therapy of amyotrophic lateral sclerosis .....</i>	<i>173</i>
<b>Cerebrovascular disease .....</b>	<b>173</b>
Treatment of stroke .....	174
Drug delivery in stroke .....	174
<i>Intraarterial administration of tissue plasminogen activator in stroke.....</i>	<i>175</i>
Drug delivery for prevention of restenosis of carotid arteries .....	176
<i>In-stent restenosis.....</i>	<i>176</i>
<i>Targeted local anti-restenotic drug delivery.....</i>	<i>177</i>
<i>Catheter-based drug delivery for restenosis .....</i>	<i>177</i>
<i>Stents for prevention of restenosis.....</i>	<i>178</i>
<i>Drug-eluting stents .....</i>	<i>178</i>
<i>Antisense approach to prevent restenosis .....</i>	<i>179</i>
Drug-eluting stents for the treatment of intracranial atherosclerosis.....	179
Tissues transplants for stroke.....	180
<i>Transplant of encapsulated tissue secreting neurotrophic factors .....</i>	<i>180</i>
Methods for delivery of neurotrophic factors in stroke.....	180
Cell therapy for stroke.....	180

<i>Stem cell transplant into the brain</i> .....	181
<i>Immortalized cell grafts for stroke</i> .....	181
<i>Intravenous infusion of marrow stromal cells</i> .....	182
<i>Intravenous infusion of umbilical cord blood stem cells</i> .....	182
<i>Future of cell therapy for stroke</i> .....	182
Gene therapy of cerebrovascular diseases .....	182
<i>Gene transfer to cerebral blood vessels</i> .....	183
<i>NOS gene therapy for restenosis</i> .....	184
Gene therapy for cerebral ischemia .....	184
<i>Gene therapy of strokes with a genetic component</i> .....	186
Drug delivery to intracranial aneurysms.....	186
Drug delivery for vasospasm following subarachnoid hemorrhage .....	186
<i>Intrathecal tissue plasminogen activator</i> .....	187
<i>Gene therapy for vasospasm</i> .....	188
<b>Drug delivery in multiple sclerosis .....</b>	<b>189</b>
An electronic device for self injection of interferon beta-1a.....	189
Oral therapies for MS .....	189
Drug delivery for MS across the BBB .....	190
<i>Delivery of methylprednisolone across the BBB</i> .....	190
<i>Monoclonal antibodies for MS and the BBB</i> .....	190
Antisense and RNAi approaches to MS .....	190
Cell therapy for multiple sclerosis.....	191
<i>Hematopoietic stem cell transplantation for multiple sclerosis</i> .....	191
<i>Embryonic stem cells and neural precursor cells for MS</i> .....	192
Gene therapy for multiple sclerosis .....	192
<b>Drug delivery in epilepsy .....</b>	<b>192</b>
Routes of administration of antiepileptic drugs.....	193
<i>Controlled-release preparations of carbamazepine</i> .....	193
<i>Intravenous carbamazepine</i> .....	193
<i>Various routes of administration of benzodiazepines</i> .....	194
Methods of delivery of novel antiepileptic therapies .....	194
<i>Regulated activation of prodrugs</i> .....	194
<i>Use of neuronal membrane transporter</i> .....	194
<i>Delivery of the antiepileptic conopeptides to the brain</i> .....	195
<i>Nasal administration of AEDs</i> .....	195
<i>Intracerebral administration of AEDs</i> .....	195
The role of drug delivery in status epilepticus .....	196
Cell therapy of epilepsy .....	197
Gene therapy for epilepsy .....	197
<i>Gene therapy for neuroprotection in epilepsy</i> .....	198
Concluding remarks on drug delivery in epilepsy.....	198
<b>Drug delivery for pain .....</b>	<b>199</b>
Intranasal delivery of analgesics .....	200
<i>Intranasal administration of morphine</i> .....	200
<i>Intranasal morphine derivatives</i> .....	201
<i>Intranasal fentanyl</i> .....	201
<i>Intranasal buprenorphine</i> .....	202
<i>Intranasal ketamine</i> .....	202
<i>Intranasal ketorolac</i> .....	202
Delivery of analgesics by inhalation.....	203
Delivery of analgesics to peripheral nerves.....	203
Spinal delivery of analgesics.....	204
<i>Epidural dexamethasone</i> .....	206
<i>Epidural morphine</i> .....	206
<i>Relief of pain by intrathecal ziconotide</i> .....	206
<i>Intrathecal neostigmine</i> .....	207
<i>Intrathecal prostaglandin antagonists</i> .....	207
<i>Intrathecal fadolmidine</i> .....	207
<i>Intrathecal siRNA for relief of neuropathic pain</i> .....	208
<i>Concluding remarks on intrathecal delivery of analgesic agents</i> .....	208
Intracerebroventricular drug delivery for pain .....	208
<i>Delivery of analgesics to the CNS across the BBB</i> .....	208
<b>Drug delivery for migraine .....</b>	<b>209</b>
Management of migraine .....	209
Novel drug delivery methods for migraine .....	210
<i>Nasal formulations for migraine</i> .....	211
<i>Sublingual spray for migraine</i> .....	212
<i>Needle-free drug delivery for migraine</i> .....	212
<b>Drug delivery for traumatic brain injury .....</b>	<b>212</b>
Cell therapy of traumatic brain injury .....	212
<i>Gene therapy for traumatic brain injury</i> .....	213



<b>Drug delivery for spinal cord injury .....</b>	<b>213</b>
Administration of neurotrophic factors for spinal cord injury .....	213
Cell therapy for spinal cord injury .....	214
<i>Transplantation of glial cells for SCI .....</i>	<i>214</i>
<i>Fetal neural grafts for SCI.....</i>	<i>214</i>
<i>Embryonic stem cells for SCI.....</i>	<i>214</i>
<i>Schwann cell transplants for SCI.....</i>	<i>216</i>
<i>Olfactory glial cells for SCI.....</i>	<i>216</i>
<i>Marrow stromal cells for SCI.....</i>	<i>216</i>
<i>Intravenous injection of stem cells for spinal cord repair.....</i>	<i>216</i>
<i>Combinatorial approach for regeneration in SCI.....</i>	<i>217</i>
<i>Cell therapy of syringomyelia .....</i>	<i>217</i>
<i>Gene therapy of spinal cord injury.....</i>	<i>217</i>
<b>Drug delivery in CNS infections.....</b>	<b>217</b>
Drug delivery in neuroAIDS.....	218
<b>Drug delivery for miscellaneous neurological disorders.....</b>	<b>218</b>
Drug delivery for CNS involvement in Hunter syndrome.....	218
Antisense therapy for spinal muscular atrophy.....	219
<i>Antisense gene splicing for SMA.....</i>	<i>219</i>
<i>Intrathecal antisense delivery.....</i>	<i>219</i>
Genetically modified stem cells for metachromatic leukodystrophy .....	219
Relief of spasticity by intrathecal baclofen .....	220
<b>Drug delivery for retinal disorders.....</b>	<b>220</b>
<i>Age-related macular degeneration.....</i>	<i>221</i>
<i>Squalamine.....</i>	<i>221</i>
<i>Combretastatin A4P for myopic macular degeneration .....</i>	<i>221</i>
<i>Gene therapy for AMD .....</i>	<i>222</i>
<i>Anti-VEGF approach to AMD .....</i>	<i>222</i>
<i>Delivery of pegaptanib for treatment of AMD.....</i>	<i>222</i>
Stem cell therapy for retinitis pigmentosa .....	223
Proliferative retinopathies .....	223
<b>Drug delivery for inner ear disorders.....</b>	<b>223</b>
Delivery of stem cells for hearing loss.....	224
Auditory hair cell replacement by gene therapy .....	224
Future prospects of drug delivery to the inner ear .....	225
<b>Drug delivery in psychiatric disorders.....</b>	<b>225</b>
Delivery of antidepressants .....	225
<i>Transdermal delivery of antidepressants .....</i>	<i>226</i>
<i>Nasal delivery of antidepressants.....</i>	<i>228</i>
Delivery methods and formulations of antipsychotics.....	228
<i>Long-acting injectable antipsychotics.....</i>	<i>229</i>
<i>Transdermal haloperidol .....</i>	<i>229</i>
<i>Transdermal risperidone for treatment of schizophrenia.....</i>	<i>230</i>
<i>Transdermal blonanserin for treatment of schizophrenia .....</i>	<i>230</i>
<i>Transnasal oxytocin for schizophrenia.....</i>	<i>230</i>
Transdermal lithium for bipolar disorder .....	230
<b>6. Drug delivery for brain tumors .....</b>	<b>232</b>
<b>Introduction .....</b>	<b>232</b>
Methods for evaluation of anticancer drug penetration into brain tumor .....	232
Innovative methods of drug delivery for glioblastoma multiforme.....	232
<b>Delivery of anticancer drugs across the blood-brain barrier .....</b>	<b>233</b>
Anticancer agents with increased penetration of BBB.....	233
BBB disruption.....	234
Nanoparticle-based targeted delivery of chemotherapy across the BBB.....	235
Tyrosine kinase inhibitor increases topotecan penetration into CNS .....	236
<b>Bypassing the BBB by alternative methods of drug delivery .....</b>	<b>237</b>
Intranasal perillyl alcohol .....	237
Intraarterial chemotherapy .....	237
<b>Enhancing tumor permeability to chemotherapy .....</b>	<b>238</b>
PDE5 inhibitors for increasing BTB permeability .....	238
<b>Local delivery of therapeutic agents into the brain .....</b>	<b>238</b>
Biodegradable microspheres containing 5-FU.....	238
Carmustine biodegradable polymer implants .....	239
Fibrin glue implants containing anticancer drugs.....	240
Interstitial delivery of dexamethasone for reduction of peritumor edema .....	240
Magnetically controlled microspheres.....	240
<b>Convection-enhanced delivery .....</b>	<b>240</b>
CED for receptor-directed cytotoxin therapy .....	240
CED of topotecan .....	241
CED of a modified diphtheria toxin conjugated to transferrin .....	241

CED of nanoliposomal CPT-11.....	241
CED for delivery <sup>131</sup> I-chTNT-1/B MAb .....	242
<b>Anticancer drug formulations for targeted delivery to brain tumors .....</b>	<b>242</b>
Intravenous delivery of anticancer agents bearing transferrin .....	242
Liposomes for drug delivery to brain tumors.....	242
MABs targeted to brain tumors .....	243
Targeted delivery of drug-peptide conjugates to GBM.....	243
Multiple targeted drugs for brain tumors .....	244
Nanoparticles for targeted drug delivery in glioblastoma multiforme .....	244
Targeted antiangiogenic/apoptotic/cytotoxic therapies.....	245
<b>Introduction of the chemotherapeutic agent into the CSF pathways .....</b>	<b>246</b>
Intraventricular chemotherapy for meningeal cancer .....	246
Intrathecal chemotherapy .....	247
<b>Photodynamic therapy for chemosensitization of brain tumors .....</b>	<b>247</b>
Nanoparticles for photodynamic therapy of brain tumors.....	247
<b>Innovative delivery of radiotherapy to brain tumors .....</b>	<b>248</b>
GliaSite Radiation Therapy System.....	248
Boron neutron capture therapy for brain tumors .....	248
<b>Cell therapy for glioblastoma multiforme.....</b>	<b>249</b>
Chimeric antigen receptor T cells .....	249
Mesenchymal stem cells to deliver treatment for gliomas .....	249
<b>Gene therapy for glioblastoma multiforme. ....</b>	<b>249</b>
Antiangiogenic gene therapy .....	250
Anticancer drug delivery by genetically engineered MSCs.....	251
Intravenous gene delivery with nanoparticles into brain tumors .....	251
Ligand-directed delivery of dsRNA molecules targeted to EGFR .....	251
Neural stem cells for drug/gene delivery to brain tumors .....	252
Peptides targeted to glial tumor cells.....	253
RNAi gene therapy of brain cancer .....	253
Single-chain antibody-targeted adenoviral vectors .....	253
Targeting normal brain cells with an AAV vector encoding interferon- $\beta$ .....	254
Treatment of medulloblastoma by suppressing genes in Shh pathway .....	254
Virus-mediated oncolytic therapy of brain cancer .....	254
<i>HIV-mediated Oncolysis.....</i>	<i>254</i>
<i>Autophagy by conditionally replicating adenoviruses.....</i>	<i>255</i>
<i>Reovirus-mediated Oncolysis.....</i>	<i>255</i>
<i>Measles virus-mediated oncolysis.....</i>	<i>256</i>
<i>Oncolytic virus targeted to brain tumor stem cells.....</i>	<i>256</i>
<i>Oncolysis with vesicular stomatitis virus .....</i>	<i>256</i>
<i>Future prospects of viral-mediated oncolysis .....</i>	<i>257</i>
<b>Vaccination for glioblastoma multiforme .....</b>	<b>257</b>
<b>7. Markets for Drug Delivery in CNS Disorders.....</b>	<b>258</b>
<b>Introduction .....</b>	<b>258</b>
Methods of calculation of CNS drug delivery markets .....	258
<b>Markets for CNS drug delivery technologies .....</b>	<b>258</b>
Drug delivery share in selected CNS markets.....	259
CNS share of drug delivery technologies .....	259
Geographical distribution of CNS drug delivery markets .....	260
<b>Impact of improved drug delivery on CNS drug markets.....</b>	<b>260</b>
Neurodegenerative disorders.....	260
<i>Alzheimer disease .....</i>	<i>261</i>
<i>Parkinson disease .....</i>	<i>261</i>
<i>Huntington disease .....</i>	<i>261</i>
<i>Amyotrophic lateral sclerosis .....</i>	<i>261</i>
Epilepsy.....	262
Migraine and other headaches .....	262
Stroke .....	262
Central nervous system trauma .....	263
Multiple sclerosis.....	263
Brain tumors .....	263
<b>Limitations of the current drug delivery technologies for CNS.....</b>	<b>264</b>
<b>Unmet needs in CNS drug delivery technologies .....</b>	<b>264</b>
<b>Future strategies for expanding CNS drug delivery markets .....</b>	<b>265</b>
Education of neurologists.....	265
Demonstration of the advantages of the newer methods of delivery .....	266
Rescue of old products by novel drug delivery methods .....	266
Facilitation of the approval process of new drugs .....	266
<b>8. Companies .....</b>	<b>268</b>
<b>Introduction .....</b>	<b>268</b>

<b>Profiles of companies.....</b>	<b>268</b>
<b>Collaborations.....</b>	<b>354</b>

**9. References..... 358**

**Tables**

Table 1-1: Landmarks in the development of drug delivery to the CNS .....	18
Table 2-1: Proteins expressed at the neurovascular unit .....	31
Table 2-2: Transporters that control penetration of molecules across the BBB .....	36
Table 2-3: Enzymes that control the penetration of molecules across the BBB .....	39
Table 2-4: Factors that increase the permeability of the BBB.....	44
Table 2-5: Diseases with associated disturbances of BBB.....	45
Table 3-1: Various methods of drug delivery to the central nervous system .....	62
Table 3-2: Drugs available for intrathecal administration .....	71
Table 3-3: Investigational drugs administered by intrathecal route .....	72
Table 3-4: Strategies for drug delivery to the CNS across the BBB .....	77
Table 3-5: Specific inhibitors of P-glycoprotein in clinical development .....	85
Table 3-6: Molecules attached to Trojan horses injected intravenously for CNS effect.....	90
Table 3-7: Examples of controlled and sustained release drug delivery for CNS disorders .....	103
Table 3-8: Novel methods of delivery of drugs for CNS disorders .....	104
Table 3-9: Indications for the clinical applications of NTFs in neurologic disorders .....	109
Table 3-10: Methods for delivery of neurotrophic factors to the CNS .....	109
Table 4-1: Methods for delivering cell therapies in CNS disorders.....	121
Table 4-2: Classification of methods of gene therapy.....	125
Table 4-3: Methods of gene transfer as applied to neurologic disorders .....	126
Table 4-4: Potential indications for gene therapy of neurologic disorders .....	131
Table 4-5: Companies developing cell/gene therapies for CNS disorders .....	133
Table 4-6: Methods of antisense delivery as applied to the CNS.....	134
Table 5-1: Strategies for the treatment of Parkinson's disease .....	142
Table 5-2: Drug delivery systems for Parkinson's disease .....	144
Table 5-3: Types of cell used for investigative treatment of Parkinson's disease .....	149
Table 5-4: Status of cell therapies in development for Parkinson's disease .....	149
Table 5-5: Gene therapy techniques applicable to Parkinson disease .....	155
Table 5-6: Companies developing gene therapy for Parkinson's disease.....	159
Table 5-7: Classification of pharmacotherapy for Alzheimer disease .....	160
Table 5-8: Novel drug delivery methods for Alzheimer disease therapies .....	161
Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	169
Table 5-10: Methods of delivery of therapies in development for ALS .....	170
Table 5-11: Classification of treatments for stroke .....	174
Table 5-12: Treatments of stroke involving innovative drug delivery methods .....	175
Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty .....	177
Table 5-14: Gene transfer in animal models of carotid artery restenosis .....	183
Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia .....	184
Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models.....	185
Table 5-17: Pharmacological agents for treatment of cerebral vasospasm .....	187
Table 5-18: Gene therapy strategies for vasospasm.....	188
Table 5-19: A classification of drug delivery methods used in management of pain .....	199
Table 5-20: Spinal administration of drugs for pain .....	204
Table 5-21: Investigational drugs for pain administered by intrathecal route .....	205
Table 5-22: Current management of migraine .....	210
Table 5-23: Novel drug delivery methods for migraine .....	210
Table 6-1: Innovative methods of drug delivery for glioblastoma multiforme.....	232
Table 6-2: Strategies for gene therapy of malignant brain tumors.....	249
Table 7-1: Share of drug delivery technologies in selected CNS markets: 2016-2026 .....	259
Table 7-2: CNS market share of drug delivery technologies 2016-2026 .....	259
Table 7-3: Value of CNS drug delivery in the major world markets from 2016-2026.....	260
Table 7-4: Limitations of the current drug delivery technologies for CNS.....	264
Table 8-1: Alkermes pipeline .....	275
Table 8-2: Collaborations of companies in CNS drug delivery .....	354

## Figures

Figure 1-1: Interaction of neurotransmitters with receptors .....	22
Figure 2-1: The neurovascular unit .....	30
Figure 2-2: Various forms of passage of substances across the blood brain barrier.....	35
Figure 2-3: Role of BBB models for drug delivery in preclinical CNS drug development .....	57
Figure 3-1: Routes of drug delivery to the brain .....	63
Figure 3-2: Penetration of CSF into spinal cord .....	70
Figure 3-3: Disposition of opioids after intrathecal administration .....	73
Figure 3-4: Use of receptor-mediated transcytosis to cross the BBB .....	92
Figure 3-5: Nanotechnology-based strategies for delivery of BDNF to the CNS .....	116
Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease .....	147
Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels .....	156
Figure 6-1: A concept of targeted drug delivery to GBM across the BBB.....	235
Figure 7-1: Unmet needs in the CNS drug delivery technologies .....	265